

## Select Hemophilia B Products

**Policy # 00863**

Original Effective Date: 01/15/2024

Current Effective Date: 02/10/2025

*Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.*

*Note: Factor VIII products are addressed separately in medical policy 00822.*

## When Services Are Eligible for Coverage

*Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:*

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider select hemophilia B products, including, but not limited to Alprolix<sup>®</sup>†, Idelvion<sup>®</sup>†, AlphaNine<sup>®</sup>†, Profilnine<sup>®</sup>†, Ixinity<sup>®</sup>†, Rebinyn<sup>®</sup>†, Benefix<sup>®</sup>†, and Rixubis<sup>®</sup>† to be **eligible for coverage.\*\***

## Background/Overview

The hemophilia products mentioned in this policy (Alprolix, Idelvion, Alphanine, Profilnine, Ixinity, Rebinyn, Benefix, and Rixubis) are approved by the Food and Drug Administration for the treatment of hemophilia B. The hemophilia products listed in this policy are covered at parity status. The lack of mention of a particular hemophilia product does not insinuate that there is no coverage for that product. This policy currently only lists Factor IX products.

## Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

The purpose of this policy is to reflect the coverage of the mentioned hemophilia B products at parity status. It should be noted that these are not targeted medical drugs. This Medical Policy is informational in nature only.

## Select Hemophilia B Products

Policy # 00863

Original Effective Date: 01/15/2024

Current Effective Date: 02/10/2025

## References

1. Alprolix [package insert]. Bioverativ Therapeutics, Inc. Cambridge, MA. Updated May 2023.
2. Kovaltry [package insert]. CSL Behring. Kankakee, IL. Updated June 2023.
3. AlphaNine SD [package insert]. Grifols USA, LLC. Los Angeles, CA. Updated June 2023.
4. Profilnine [package insert]. Grifols USA, LLC. Los Angeles, CA. Updated June 2023.
5. Ixinity [package insert]. Medexus Pharma, Inc. Chicago, IL. Updated December 2022.
6. Rebinyn [package insert]. Novo Nordisk. Bagsvaerd, Denmark. Updated August 2022.
7. Benefix [package insert]. Wyeth BioPharma. Philadelphia, PA. Updated March 2023.
8. Rixubis [package insert]. Takeda Pharmaceuticals America, Inc. Lexington, MA. Updated March 2023.

## Policy History

Original Effective Date: 01/15/2024

Current Effective Date: 02/10/2025

01/04/2024 Medical Policy Committee review

01/10/2024 Medical Policy Implementation Committee approval. New policy.

01/02/2025 Medical Policy Committee review

01/08/2025 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 01/2026

**\*\*Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.



## Select Hemophilia B Products

Policy # 00863

Original Effective Date: 01/15/2024

Current Effective Date: 02/10/2025

**NOTICE:** If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

**NOTICE:** Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

